Literature DB >> 21159748

Regulation of glutamate release by α7 nicotinic receptors: differential role in methamphetamine-induced damage to dopaminergic and serotonergic terminals.

Nicole A Northrop1, Laura P Smith, Bryan K Yamamoto, David J Eyerman.   

Abstract

Regulation of glutamate release is an important underlying mechanism in mediating excitotoxic events such as damage to dopamine (DA) and serotonin (5-HT) neurons observed after exposure to methamphetamine (Meth). One way to regulate glutamate release may be through the modulation of α7 nicotinic acetylcholine (nACh) receptors. Meth administration is known to increase acetylcholine release; however, it is unknown whether Meth increases glutamate release and causes long-term damage to both DA and 5-HT terminals through the activation of α7 nACh receptors. To test this hypothesis, the α7 nACh receptor antagonist, methyllycaconitine (MLA), was administered before the administration of repeated doses of Meth while simultaneously monitoring extracellular striatal glutamate with in vivo microdialysis. In addition, the subsequent long-term decreases in markers of dopaminergic and serotonergic terminals, including DA reuptake transporter (DAT), serotonin reuptake transporter (SERT), vesicular monoamine transporter-2, vesicular DA, and vesicular 5-HT content in the rat striatum, were measured. The results show that MLA pretreatment prevented Meth-induced increases in striatal glutamate and protected against the subsequent long-term decreases in striatal DAT and vesicular DA content without affecting the hyperthermia produced by Meth. In contrast, the Meth-induced decreases in striatal SERT immunoreactivity and vesicular 5-HT content were not affected by MLA. This suggests that the α7 nACh receptor differentially mediates glutamate-dependent damage to DA but not 5-HT terminals in a manner that is independent of hyperthermia. Furthermore, antagonism of α7 nACh receptors may be a possible therapeutic strategy for decreasing extracellular glutamate and preventing the excitotoxic damage observed in other DA-related neurodegenerative disorders.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21159748      PMCID: PMC3061539          DOI: 10.1124/jpet.110.177287

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  40 in total

1.  Presynaptic nicotinic receptors modulating dopamine release in the rat striatum.

Authors:  S Wonnacott; S Kaiser; A Mogg; L Soliakov; I W Jones
Journal:  Eur J Pharmacol       Date:  2000-03-30       Impact factor: 4.432

2.  Dose-related neuroprotective effects of chronic nicotine in 6-hydroxydopamine treated rats, and loss of neuroprotection in alpha4 nicotinic receptor subunit knockout mice.

Authors:  R E Ryan; S A Ross; J Drago; R E Loiacono
Journal:  Br J Pharmacol       Date:  2001-04       Impact factor: 8.739

3.  AMPA-kainate subtypes of glutamate receptor in rat cerebral microglia.

Authors:  M Noda; H Nakanishi; J Nabekura; N Akaike
Journal:  J Neurosci       Date:  2000-01-01       Impact factor: 6.167

4.  The effects of methamphetamine on serotonin transporter activity: role of dopamine and hyperthermia.

Authors:  H M Haughey; A E Fleckenstein; R R Metzger; G R Hanson
Journal:  J Neurochem       Date:  2000-10       Impact factor: 5.372

5.  Direct evidence that release-stimulating alpha7* nicotinic cholinergic receptors are localized on human and rat brain glutamatergic axon terminals.

Authors:  Mario Marchi; Francesca Risso; Concetta Viola; Paolo Cavazzani; Maurizio Raiteri
Journal:  J Neurochem       Date:  2002-03       Impact factor: 5.372

6.  Peroxynitrite inactivates the human dopamine transporter by modification of cysteine 342: potential mechanism of neurotoxicity in dopamine neurons.

Authors:  Samuel U Park; Jasmine V Ferrer; Jonathan A Javitch; Donald M Kuhn
Journal:  J Neurosci       Date:  2002-06-01       Impact factor: 6.167

7.  Methylphenidate alters vesicular monoamine transport and prevents methamphetamine-induced dopaminergic deficits.

Authors:  Verónica Sandoval; Evan L Riddle; Glen R Hanson; Annette E Fleckenstein
Journal:  J Pharmacol Exp Ther       Date:  2003-03       Impact factor: 4.030

8.  A study on the mechanisms by which minocycline protects against MDMA ('ecstasy')-induced neurotoxicity of 5-HT cortical neurons.

Authors:  Laura Orio; Noemi Llopis; Elisa Torres; Maria Izco; Esther O'Shea; M Isabel Colado
Journal:  Neurotox Res       Date:  2009-09-24       Impact factor: 3.911

9.  Alpha7 nicotinic receptor activation inhibits ethanol-induced mitochondrial dysfunction, cytochrome c release and neurotoxicity in primary rat hippocampal neuronal cultures.

Authors:  Yangxin Li; Edwin M Meyer; Don W Walker; William J Millard; Yun-Ju He; Michael A King
Journal:  J Neurochem       Date:  2002-05       Impact factor: 5.372

10.  Effects of activation of NMDA and AMPA glutamate receptors on the extracellular concentrations of dopamine, acetylcholine, and GABA in striatum of the awake rat: a microdialysis study.

Authors:  L F Hernández; G Segovia; F Mora
Journal:  Neurochem Res       Date:  2003-12       Impact factor: 3.996

View more
  11 in total

1.  Chronic Nicotine Exposure Attenuates Methamphetamine-Induced Dopaminergic Deficits.

Authors:  Paula L Vieira-Brock; Lisa M McFadden; Shannon M Nielsen; Jonathan D Ellis; Elliot T Walters; Kristen A Stout; J Michael McIntosh; Diana G Wilkins; Glen R Hanson; Annette E Fleckenstein
Journal:  J Pharmacol Exp Ther       Date:  2015-09-21       Impact factor: 4.030

Review 2.  Neuroimmune basis of methamphetamine toxicity.

Authors:  Jennifer M Loftis; Aaron Janowsky
Journal:  Int Rev Neurobiol       Date:  2014       Impact factor: 3.230

3.  Cyclooxygenase activity contributes to the monoaminergic damage caused by serial exposure to stress and methamphetamine.

Authors:  Nicole A Northrop; Bryan K Yamamoto
Journal:  Neuropharmacology       Date:  2013-05-02       Impact factor: 5.250

4.  Argon prevents the development of locomotor sensitization to amphetamine and amphetamine-induced changes in mu opioid receptor in the nucleus accumbens.

Authors:  Hélène N David; Martine Dhilly; Géraldine Poisnel; Mickael Degoulet; Cédric Meckler; Nicolas Vallée; Jean-Éric Blatteau; Jean-Jacques Risso; Marc Lemaire; Danièle Debruyne; Jacques H Abraini
Journal:  Med Gas Res       Date:  2014-12-29

5.  Ethanol-induced alterations of amino acids measured by in vivo microdialysis in rats: a meta-analysis.

Authors:  Sarah Fliegel; Ines Brand; Rainer Spanagel; Hamid R Noori
Journal:  In Silico Pharmacol       Date:  2013-05-17

6.  Circulating brain microvascular endothelial cells (cBMECs) as potential biomarkers of the blood-brain barrier disorders caused by microbial and non-microbial factors.

Authors:  Sheng-He Huang; Lin Wang; Feng Chi; Chun-Hua Wu; Hong Cao; Aimin Zhang; Ambrose Jong
Journal:  PLoS One       Date:  2013-04-26       Impact factor: 3.240

7.  The effects of locus coeruleus and norepinephrine in methamphetamine toxicity.

Authors:  Michela Ferrucci; Filippo S Giorgi; Alessia Bartalucci; Carla L Busceti; Francesco Fornai
Journal:  Curr Neuropharmacol       Date:  2013-01       Impact factor: 7.363

8.  Prenatal nicotinic exposure upregulates pulmonary C-fiber NK1R expression to prolong pulmonary C-fiber-mediated apneic response.

Authors:  Lei Zhao; Jianguo Zhuang; Na Zang; Yong Lin; Lu-Yuan Lee; Fadi Xu
Journal:  Toxicol Appl Pharmacol       Date:  2015-10-30       Impact factor: 4.460

9.  Functional Impact of 14 Single Nucleotide Polymorphisms Causing Missense Mutations of Human α7 Nicotinic Receptor.

Authors:  Qinhui Zhang; Yingjie Du; Jianliang Zhang; Xiaojun Xu; Fenqin Xue; Cong Guo; Yao Huang; Ronald J Lukas; Yongchang Chang
Journal:  PLoS One       Date:  2015-09-04       Impact factor: 3.240

10.  Argon blocks the expression of locomotor sensitization to amphetamine through antagonism at the vesicular monoamine transporter-2 and mu-opioid receptor in the nucleus accumbens.

Authors:  H N David; M Dhilly; M Degoulet; G Poisnel; C Meckler; N Vallée; J-É Blatteau; J-J Risso; M Lemaire; D Debruyne; J H Abraini
Journal:  Transl Psychiatry       Date:  2015-07-07       Impact factor: 6.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.